Elective Cardiac Surgery Clinical Trial
— REFRESH II-AKIOfficial title:
CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery (REFRESH II Trial)
Verified date | August 2022 |
Source | CytoSorbents, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prospective, multi-center, randomized, blinded, pivotal clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care plus treatment with the CytoSorb® device.
Status | Terminated |
Enrollment | 116 |
Est. completion date | January 18, 2022 |
Est. primary completion date | January 18, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Scheduled for non-emergent cardiac surgery requiring CPB for i) heart valve replacement with any other procedure, without hypothermic circulatory arrest (HCA), or ii) aortic reconstruction with or without another procedure, with HCA Exclusion Criteria: - Isolated Coronary Artery Bypass Graft - Pregnant women - Life expectancy of < 14 days - End stage organ disease - Active infection - Correction of a congenital heart defect - Contraindication to anticoagulation with heparin - Minimally invasive surgery implantation (TAVI) or transcatheter aortic valve replacement (TAVR) - Declined informed consent |
Country | Name | City | State |
---|---|---|---|
United States | University of Maryland | Baltimore | Maryland |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | University of Chicago | Chicago | Illinois |
United States | The Christ Hospital Linder Research Center | Cincinnati | Ohio |
United States | Ohio State university | Columbus | Ohio |
United States | Duke University Medical Center | Durham | North Carolina |
United States | East Carolina University | Greenville | North Carolina |
United States | Baylor College of Medicine | Houston | Texas |
United States | Indiana University Health Methodist Hospital | Indianapolis | Indiana |
United States | University of Louisville | Louisville | Kentucky |
United States | Baptist Memorial Hospital | Memphis | Tennessee |
United States | Vanderbilt University | Nashville | Tennessee |
United States | Yale School of Medicine | New Haven | Connecticut |
United States | Columbia University Medical Center | New York | New York |
United States | Northwell Health: Lennox Hill Hospital | New York | New York |
United States | Integris Baptist Medical Center | Oklahoma City | Oklahoma |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Maine Medical Center | Portland | Maine |
United States | Valley Hospital | Ridgewood | New Jersey |
United States | Iowa Heart Center | West Des Moines | Iowa |
Lead Sponsor | Collaborator |
---|---|
CytoSorbents, Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence or severity of acute kidney injury (AKI) in the first 48 hours after cardiopulmonary pulmonary bypass (CPB) | Kidney Disease Improving Global Outcomes (KDIGO) definitions for AKI | From start of CPB through 48 hours after CPB | |
Secondary | Change in maximum plasma free hemoglobin and activated complement from start of CPB through post-surgery day 3 | Blood sample indices of effects from cardiac surgery with CPB | From start of CPB through post-surgery day 3 | |
Secondary | Severity or duration of AKI in the first 7 days after CPB | KDIGO definitions for AKI | From start of CPB through 7 days post-cardiac surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02838524 -
Acceptable Range of Inspiratory Effort During Mechanical Ventilation
|
||
Completed |
NCT02566525 -
CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery
|
N/A | |
Completed |
NCT00879931 -
Influence of Corticoids on Renal Function in Cardiac Surgery
|
Phase 2 | |
Recruiting |
NCT05662501 -
Pleiades Safety and Feasibility Study
|
N/A | |
Completed |
NCT02407873 -
Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery
|
N/A | |
Not yet recruiting |
NCT01418521 -
Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery
|
Phase 4 | |
Completed |
NCT01748266 -
Microcirculation of the Thenar Eminence
|
N/A |